Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
TBPH
#2558
Theravance Biopharma, Inc. - Ordinary Shares
16.9
3
USD
0.00%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+0.18%
Monthly Change
+1.93%
6 month change
-17.74%
Year Change
+17.98%
Previous Close
16.9
0
Open
16.9
2
Low
16.9
0
High
16.9
4
Volume
47
Markets
US Stock Market
Healthcare
Biotechnology
TBPH
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
Current
Key stats
Total common shares outstanding
64.33 M
74.7 M
62.86 M
48.16 M
49.47 M
51.49 M
51.55 M
Valuation ratios
Enterprise value
1.29 B
963.47 M
391.45 M
518.68 M
427.72 M
795.63 M
599.64 M
Price to earnings ratio
-3.98
-3.85
0.93
-11.59
-8.18
9.08
7.83
Price to sales ratio
15.42
13.88
15.72
11.16
7.14
8.97
8.06
Price to cash flow ratio
-4.42
-3.69
-4.32
-23.74
-39.85
4.04
3.26
Price to book ratio
-3.65
-2.27
1.83
3.01
2.62
3.25
0.85
Enterprise value to EBITDA ratio
-4.56
-3.97
-4.6
-9.95
-9.8
-1 671.48
203.75
Profitability ratios
Return on assets %
-0.59
-0.53
1.44
-0.14
-0.16
0.22
-0.01
Return on equity %
0.92
0.59
1.97
-0.26
-0.32
0.36
-0.02
Return on invested capital %
-801.4
-621.63
-163.51
-73.03
-53.24
-7.96
-26.46
Gross margin %
100
100
100
100
100
100
100
Operating margin %
-414.37
-466.06
-179.09
-97.58
-72.92
-3.35
-53.58
EBITDA margin %
-392.94
-438.26
-165.75
-90.79
-67.78
-0.44
-51.43
Net margin %
-386.9
-360.55
1 698.54
-96.11
-87.63
98.54
-27.87
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
3.18
4.26
12.31
5.39
5.02
10.93
13.14
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.16
0.13
0.1
0.12
0.17
0.22
0.04
Solvency ratios
Debt to assets ratio
0.48
0.61
—
—
—
—
—
Debt to equity ratio
-0.75
-0.67
—
—
—
—
—
Long term debt to total assets ratio
1.32
1.64
1.01
0
—
—
—
Long term debt to total equity ratio
-2.04
-1.82
1.4
0
—
—
—
Per share metrics
Operating cash flow per share
-4.02
-2.99
-2.54
-0.49
-0.24
4.63
5.29
EBIT per share
-4.78
-3.71
-1.25
-1.01
-0.96
-0.07
0.03
EBITDA per share
-4.53
-3.49
-1.16
-0.94
-0.89
-0.01
0.06
Total debt per share
3.64
3.28
—
—
—
—
—
Cash per share
4.7
2.5
4.45
1.85
1.81
6.12
7.7
Net current asset value per share
6.31
3.6
4.8
2.41
3.3
8.12
8.14
Tangible book value per share
-4.87
-4.87
6
3.85
3.59
5.76
5.67
Working capital per share
4.33
2.75
4.41
1.97
2.64
7.38
7.52
Book value per share
-4.87
-4.87
6
3.85
3.59
5.76
5.67
News
Here’s Why Zymeworks Inc. Paid $929M For Theravance Biopharma (NASDAQ:ZYME)
Theravance Stock Down 3% After Zymeworks Announces Buyout
Silence Therapeutics (SLN) Surges 26.0%: Is This an Indication of Further Gains?
Are Options Traders Betting on a Big Move in Theravance Biopharma Stock?
TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle
Here's Why Theravance Biopharma (TBPH) is a Strong Momentum Stock
Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates
CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised
Theravance Biopharma: A Special Situation With A 50-100% Likely Upside (TBPH)
Theravance Stock Declines Around 17% in Three Months: Here's Why
Here's Why Theravance Biopharma (TBPH) is a Strong Momentum Stock
Theravance's Q4 Earnings and Revenues Miss Estimates